vTv Therapeutics Inc. (VTVT) Stock

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is led by CEO Paul J. Sekhri, employs 23 people, headquartered in US, publicly traded since 2015.

vTv Therapeutics Inc. (VTVT) stock trades at $25.55 with a market capitalization of $101.02M. The stock is valued at a negative price-to-earnings (P/E) ratio of -277.91, reflecting a net loss over the last twelve months, price-to-book of 4.82, price-to-sales of 2.17. Over the past 52 weeks the stock has ranged between $19.50 and $44.00, and currently trades 41.9% below its 52-week high.

On profitability, vTv Therapeutics Inc. generates a return on equity (ROE) of -6.27% (negative, reflecting a net loss), return on capital employed of -11.48%, an operating margin of -8.26%, a net profit margin of -12.91%.

vTv Therapeutics Inc. by the numbers, 2016–2025

Between 2016 and 2025 vTv Therapeutics Inc. reported revenue of $1.0M rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-27.0M.

The most recent net margin is -12.91%. On a trailing twelve-month basis to Jun '26, revenue is $37.0M and net profit $-5.0M.

Borrowings fell from $11.0M to $0, cash from operations was $-25.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 38.1% over five years, and was -42.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

vTv Therapeutics Inc. (VTVT) — frequently asked questions